DBV TECHNOLOGIE/S (NASDAQ:DBVT) Receives $13.18 Consensus Price Target from Analysts

Share on StockTwits

DBV TECHNOLOGIE/S (NASDAQ:DBVT) has been assigned a consensus rating of “Hold” from the twelve ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $13.18.

A number of equities analysts have weighed in on the stock. Goldman Sachs Group assumed coverage on shares of DBV TECHNOLOGIE/S in a research report on Monday, June 17th. They set a “buy” rating and a $14.00 target price for the company. Zacks Investment Research lowered shares of DBV TECHNOLOGIE/S from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th. ValuEngine upgraded shares of DBV TECHNOLOGIE/S from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, BidaskClub upgraded shares of DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a research report on Thursday, August 15th.

Large investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC raised its position in DBV TECHNOLOGIE/S by 10.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 13,284 shares of the company’s stock worth $109,000 after buying an additional 1,229 shares during the last quarter. Quantamental Technologies LLC grew its stake in shares of DBV TECHNOLOGIE/S by 63.9% during the 1st quarter. Quantamental Technologies LLC now owns 4,917 shares of the company’s stock valued at $38,000 after acquiring an additional 1,917 shares during the period. FNY Investment Advisers LLC bought a new position in shares of DBV TECHNOLOGIE/S during the 2nd quarter valued at approximately $102,000. LeJeune Puetz Investment Counsel LLC bought a new position in shares of DBV TECHNOLOGIE/S during the 2nd quarter valued at approximately $108,000. Finally, Parametric Portfolio Associates LLC boosted its stake in DBV TECHNOLOGIE/S by 27.5% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 66,958 shares of the company’s stock worth $550,000 after purchasing an additional 14,454 shares during the period. Institutional investors and hedge funds own 44.99% of the company’s stock.

NASDAQ:DBVT traded down $0.14 on Friday, reaching $8.93. 553 shares of the company’s stock were exchanged, compared to its average volume of 159,702. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.34 and a quick ratio of 3.30. The firm has a market cap of $551.89 million, a price-to-earnings ratio of -2.64 and a beta of 1.82. DBV TECHNOLOGIE/S has a 52 week low of $3.60 and a 52 week high of $25.77. The stock has a fifty day simple moving average of $9.61 and a 200-day simple moving average of $8.88.

About DBV TECHNOLOGIE/S

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

Recommended Story: Earnings Reports

Analyst Recommendations for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Aptiv PLC  Receives $92.37 Consensus Target Price from Analysts
Aptiv PLC Receives $92.37 Consensus Target Price from Analysts
-$0.47 EPS Expected for Idera Pharmaceuticals Inc  This Quarter
-$0.47 EPS Expected for Idera Pharmaceuticals Inc This Quarter
Megacoin  Achieves Market Cap of $182,767.00
Megacoin Achieves Market Cap of $182,767.00
GMB Trading Up 9.6% Over Last Week
GMB Trading Up 9.6% Over Last Week
Garlicoin Price Reaches $0.0007
Garlicoin Price Reaches $0.0007
SALT Price Reaches $0.0821 on Major Exchanges
SALT Price Reaches $0.0821 on Major Exchanges


© 2006-2019 Ticker Report